229 related articles for article (PubMed ID: 15465013)
1. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.
Ko YH; Smith BL; Wang Y; Pomper MG; Rini DA; Torbenson MS; Hullihen J; Pedersen PL
Biochem Biophys Res Commun; 2004 Nov; 324(1):269-75. PubMed ID: 15465013
[TBL] [Abstract][Full Text] [Related]
2. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production.
Geschwind JF; Ko YH; Torbenson MS; Magee C; Pedersen PL
Cancer Res; 2002 Jul; 62(14):3909-13. PubMed ID: 12124317
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
Pereira da Silva AP; El-Bacha T; Kyaw N; dos Santos RS; da-Silva WS; Almeida FC; Da Poian AT; Galina A
Biochem J; 2009 Feb; 417(3):717-26. PubMed ID: 18945211
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
5. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.
Mathupala SP; Ko YH; Pedersen PL
Semin Cancer Biol; 2009 Feb; 19(1):17-24. PubMed ID: 19101634
[TBL] [Abstract][Full Text] [Related]
6. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.
Shinozaki K; Ebert O; Woo SL
Hepatology; 2005 Jan; 41(1):196-203. PubMed ID: 15619242
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
Kojiro S; Yano H; Ogasawara S; Momosaki S; Takemoto Y; Nishida N; Kojiro M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):129-37. PubMed ID: 16706824
[TBL] [Abstract][Full Text] [Related]
8. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.
Semela D; Piguet AC; Kolev M; Schmitter K; Hlushchuk R; Djonov V; Stoupis C; Dufour JF
J Hepatol; 2007 May; 46(5):840-8. PubMed ID: 17321636
[TBL] [Abstract][Full Text] [Related]
9. [Study of antitumous effect of the complex prescription of Chinese crude drug in athymic mice with HCC].
Sun BG; Chen ZX; Zhang SJ; Liu YD; Huang HZ; Yin LR
Zhong Yao Cai; 2007 Nov; 30(11):1417-21. PubMed ID: 18323213
[TBL] [Abstract][Full Text] [Related]
10. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting.
Ganapathy-Kanniappan S; Kunjithapatham R; Geschwind JF
Anticancer Res; 2013 Jan; 33(1):13-20. PubMed ID: 23267123
[TBL] [Abstract][Full Text] [Related]
11. Glucose-dependent active ATP depletion by koningic acid kills high-glycolytic cells.
Kumagai S; Narasaki R; Hasumi K
Biochem Biophys Res Commun; 2008 Jan; 365(2):362-8. PubMed ID: 17997978
[TBL] [Abstract][Full Text] [Related]
12. Regulation of blood glucose by hypothalamic pyruvate metabolism.
Lam TK; Gutierrez-Juarez R; Pocai A; Rossetti L
Science; 2005 Aug; 309(5736):943-7. PubMed ID: 16081739
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
Kim W; Yoon JH; Kim JR; Jang IJ; Bang YJ; Kim YJ; Lee HS
Cancer Chemother Pharmacol; 2009 Aug; 64(3):497-507. PubMed ID: 19096848
[TBL] [Abstract][Full Text] [Related]
14. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma.
Lee TK; Man K; Ho JW; Wang XH; Poon RT; Xu Y; Ng KT; Chu AC; Sun CK; Ng IO; Sun HC; Tang ZY; Xu R; Fan ST
Clin Cancer Res; 2005 Dec; 11(23):8458-66. PubMed ID: 16322309
[TBL] [Abstract][Full Text] [Related]
15. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
16. 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis.
Kar S; Wang M; Carr BI
Cancer Chemother Pharmacol; 2008 Oct; 62(5):831-40. PubMed ID: 18246350
[TBL] [Abstract][Full Text] [Related]
17. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase.
Ko YH; Pedersen PL; Geschwind JF
Cancer Lett; 2001 Nov; 173(1):83-91. PubMed ID: 11578813
[TBL] [Abstract][Full Text] [Related]
18. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
[TBL] [Abstract][Full Text] [Related]
19. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D
Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417
[TBL] [Abstract][Full Text] [Related]
20. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase.
Marín-Hernández A; Rodríguez-Enríquez S; Vital-González PA; Flores-Rodríguez FL; Macías-Silva M; Sosa-Garrocho M; Moreno-Sánchez R
FEBS J; 2006 May; 273(9):1975-88. PubMed ID: 16640561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
